Condition category
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims
Survival following colon or breast cancer is now possible for 50 to 80% of patients who receive chemotherapy. Studies have found that increased physical activity and regular exercise have favorable physical, functional and emotional effects during chemotherapy. Furthermore, sustained exercise of moderate to high intensity may improve long-term survival. The aim of this study is to investigate whether it is possible to support and motivate previously inactive patients to initiate and maintain physical activity during and after their chemotherapy treatment and to increase their physical fitness.

Who can participate?
Sedentary (inactive) patients with colon or breast cancer receiving chemotherapy.

What does the study involve?
This study tests the feasibility and effectiveness of two 12-week programs of varying intensity and exercise setting. All participants receive the oncologist’s advice to meet national recommendations for physical activity. Participants are randomly assigned to one of three groups. The first group receives a supervised 12-week hospital-based moderate-to-high intensity physical training program. The second group receives a non-supervised 12-week home-based program with a view to increasing their physical activity to the minimum national recommendations of 150 minutes of moderate activity plus at least two times 20 minutes of strenuous activity per week. The third group are offered one of the two exercise programs after the 12-week period.

What are the possible benefits and risks of participating?
Not provided at time of registration.

Where is the study run from?
The hospital exercise facilities are located at the Copenhagen University Hospital Rigshospitalet and are a part of Center for Integrated Rehabilitation (CIRE) affiliated to Copenhagen University, Faculty of Health Sciences.

When is the study starting and how long is it expected to run for?
January 2012 to January 2013.

Who is funding the study?
Novo Nordic Foundation and the Danish Cancer Society.

Who is the main contact?
Tom Møller

Trial website

Contact information



Primary contact

Mr Tom Møller


Contact details

Copenhagen University Hospital Rigshospitalet Department 9701
Blegdamsvej 9
+45 (0)3545 7366

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title

At cancer diagnosis – A ‘window of opportunity’ for behavioural change towards physical activity for colon and breast cancer patients: a randomised feasibility study


Study hypothesis

The overall hypothesis is that intervention initiated early in the treatment of (pre-diagnostic) non-workout accustomed patients with breast and colon cancer will increase the aerobic capacity, physical activity, improve patients reaction control and functional, emotional and social capacity and reduce the risk of lifestyle comorbidity.

A supervised hospital-based multidimensional intervention compared with an unsupervised home pedometer-based intervention after 12 weeks will be more effective in relation to:
1. Increase the maximal oxygen uptake (VO2-peak) and muscle strength (1 RM)
2. To motivate patients to improve and maintain their physical activity level of 150 min /week and at least 20 minutes strenuous exercise twice weekly
3. To improve vitality, functional capacity, general well being, pain, sleep problems, fatigue and depression
4. To promote health behaviour (smoking), social integration and return to work

Ethics approval

1. Ethical Committee of the Capital Region Copenhagen Denmark, 19/12/2011, ref: H-1-2011-131
2. The Danish Data Protection Agency, ref: 2011-41-6349

Study design

Three-armed randomised feasibility study

Primary study design


Secondary study design

Randomised controlled trial

Trial setting


Trial type


Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet


Colon and breast cancers receiving adjuvant chemotherapy


Two interventions are tested with a comparable control group. All study group participants receives the oncologists advice of meeting national recommendations for physical activity. The two intervention groups receives motivational and individual counseling to support behavioural change towards increased physical activity.

Intervention 1: A supervised 12-week hospital-based moderate-to high-intensive physical training program equivalent to 40 metabolic equivalent (MET) / week. Includes various types of cardiovascular fitness activities, muscular strength, relaxation and massage.

Intervention 2: A non-supervised 12-week progressive pedometer program with a view to increasing participants physical activity to the minimum national recommendations of 150 minutes of moderate activity plus two times 20 minutes of strenuous activity / week.

Control: Control group participants are offered one of the two intervention after 12 weeks.

Intervention type



Not Applicable

Drug names

Primary outcome measure

Maximum oxygen uptake - VO2-peak measured baseline and at 6, 12 and 39 weeks

Secondary outcome measures

1. Dual Energy X-ray Absorptiometry / DXA scan (Baseline and 12 weeks)
2. Muscular strength (baseline and at 6, 12 and 39 weeks)
3. Blood cholesterols (baseline, 12 and 39 weeks)
4. Blood pressure, pulse (baseline and 6, 12 and 39 weeks)
5. Body Mass index (baseline and 6, 12 and 39 weeks)
6. Performance status (baseline and 6, 12 and 39 weeks)
7. Self-reported physical activity, Quality of Life (EORTC QLQ C-30) (baseline and at 6, 12 and 39 weeks)
8. General Wellbeing (SF 36) (baseline and at 6, 12 and 39 weeks)
9. Anxiety and Depression (HADs) (baseline and at 6, 12 and 39 weeks)
10. Motivational readiness (baseline and at 6, 12 and 39 weeks)
11. Decisional balance (baseline and at 6, 12 and 39 weeks)
12. Exercise self-efficacy (baseline and at 6, 12 and 39 weeks)
13. Social support, (baseline and at 6, 12 and 39 weeks)
14. Labor market affiliation - Questions on matters relating to work for people who have a cancer and consist of 13 items (baseline and at 12 and 39 weeks)
15. Cardiovascular comorbidity
16. Disease free survival and recurrence (mainly 1 and 2 year follow-up data in the following RCT)

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Patients diagnosed with breast cancer (stage I - III) or colon cancer (stage II and III) in adjuvant chemotherapy
2. WHO performance status of 0 or 1
3. Aged 18 + years who do not meet criteria for recommended physical activity levels of 150 min/week of moderate leisure time physical activity, and exercises at least 20 minutes of strenuous physical activity twice a week

Participant type


Age group




Target number of participants

Feasibility study n=45

Participant exclusion criteria

1. Patients with myocardial infarction within the past three months
2. Symptomatic heart failure
3. Angina pectoris
4. Abnormal pathological ECG

Recruitment start date


Recruitment end date



Countries of recruitment


Trial participating centre

Copenhagen University Hospital Rigshospitalet Department 9701

Sponsor information


Novo Nordic Foundation (Novo Nordisk Fonden) (Denmark)

Sponsor details

Tuborg Havnevej 19
Hellerup Copenhagen
+45 (0)3527 6600

Sponsor type

Research organisation



Funder type


Funder name

Novo Nordic Foundation (Denmark)

Alternative name(s)

Funding Body Type

Funding Body Subtype


Funder name

Danish Cancer Society (Denmark)

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Basic results (scientific)

Publication list

Publication citations

Additional files

Editorial Notes